Development of Dendritic Cell-Based Prostate Cancer Vaccine

  • Benjamin A. Tjoa
  • Gerald P. Murphy
Part of the Contemporary Cancer Research book series (CCR)


Current prostate cancer treatments include surgery, radiotherapy, chemotherapy, and hormone therapy. Efforts in early detection of prostate cancer—which include serum prostate specific antigen (PSA) screening and digital rectal examination—have allowed for diagnoses of the disease at its earliest stages. Treatment strategies such as radical prostatectomy and local radiotherapy are largely successful for patients with clinically localized prostate cancer (14,32,64). Brachytherapy is an example of a novel method to introduce radioisotopes to localized cancer tissues (40). This method implants radioactive seeds directly into tumor sites, minimizing exposure to surrounding tissues. A 10-yr follow-up study involving brachytherapy treatment of 152 consecutive patients with clinically organ confined prostate carcinoma reported a disease-free rate of 64% (41). However, up to one-third of patients initially diagnosed with clinically localized disease and treated with conventional treatments may eventually develop metastases (20).


Prostate Cancer Dendritic Cell Granulocyte Macrophage Colony Stimulate Factor Cancer Vaccine Prostatic Acid Phosphatase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, et al. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175: 1586–1593.PubMedCrossRefGoogle Scholar
  2. 2.
    Austyn, J. 1996. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 180: 1287–1292.CrossRefGoogle Scholar
  3. 3.
    Berhard, H., M. L. Disis, S. Heimfeld, S. Hand, J. R. Gralow, and M. A. Cheever. 1995. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55: 1099–1104.Google Scholar
  4. 4.
    Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, et al. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1 /Melan A. Cancer J. Sci. Am. 3: 37–44.PubMedGoogle Scholar
  5. 5.
    DeVita, Jr., V. 1997. Principles of chemotherapy, in Cancer Principles & Practice of Oncology ( DeVita, Jr., S. Hellman, and S. Rosenberg, eds.), Lippincott, Philadelphia, PA, p. 276.Google Scholar
  6. 6.
    Engelhard, V. H. 1994. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12: 181–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, et al. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24: 605–610.PubMedCrossRefGoogle Scholar
  8. 8.
    Foti, A. G., J. F. Cooper, H. Herschman, and R. R. Malvaez. 1977. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N. Engl. J. Med. 297: 1357–1361.PubMedCrossRefGoogle Scholar
  9. 9.
    Fung, P. Y. S., M. Madej, R. R. Koganty, and B. M. Longenecker. 1992. Active specificimmunotherapy of a murine mammary adenocarcinoma using a specific tumor-associated glycoconjugate. Cancer Res. 50: 4308–4311.Google Scholar
  10. 10.
    Grabbe, S., S. Beissert, T. Schwarz, and R. D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16: 117–121.Google Scholar
  11. 11.
    Grabbe, S., S. Bruvers, R. L. Gallo, T. L. Knisely, R. Nazareno, and R. D. Grandstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146: 3656–3661.PubMedGoogle Scholar
  12. 12.
    Gupta, R. K. and G. R. Siber. 1995. Adjuvants for human vaccines-current status, problems, and future prospects. Vaccine 13: 1263–1276.PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta, R. K., C. L. Varanelli, P. Griffin, D. F. Wallach, and G. R. Siber. 1996. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens (published erratum appears in Vaccine 1996 Jun;14[8]:1). Vaccine 14: 219–225.PubMedCrossRefGoogle Scholar
  14. 14.
    Hanks, G., J. Krall, A. Hanlon, S. Asbell, M. Pilepich, and J. Owen. 1994. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int. J. Radiat. Oncol. Biol. Phys. 28: 39–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Helling, F., S. Zhang, A. Shang, S. Adluri, M. Calves, R. Koganty, et al. 1995. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55: 2783–2788.PubMedGoogle Scholar
  16. 16.
    Horoszewicz, J. S., E. Kawinski, and G. P. Murphy. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res. 7: 927–936.PubMedGoogle Scholar
  17. 17.
    Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52–28.Google Scholar
  18. 18.
    Israeli, R. S., C. T. Powell, J. G. Con, W. R. Fair, and W. Heston. 1993. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 54: 1807–1811.Google Scholar
  19. 19.
    Iverson, P. 1998. Orchidectomy and oestrogen therapy revisited. Eur. Urol. 34 (Suppl.): 7–11.CrossRefGoogle Scholar
  20. 20.
    Jones, G., C. Mettlin, G. Murphy, P. Guinan, H. Herr, D. Hussey, et al. 1995. Patterns of care for carcinoma of the prostate gland; results of a national survey of 1984 and 1990. J. Am. Coll. Surg. 545–554.Google Scholar
  21. 21.
    Kappler, J. N. Roehm, and P. T. Marrack. 1987. Cell tolerance by clonal elimination in the thymus. Cell 49: 273–280.Google Scholar
  22. 22.
    Kawakami, M. and J. Nakayama. 1997. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 15: 2321–2324.Google Scholar
  23. 23.
    Knight, S. C. and A. J. Stagg. 1993. Antigen-presenting cell types. Curr. Opin. Immunol. 5: 374–382.PubMedCrossRefGoogle Scholar
  24. 24.
    Knight, S. C., R. Hunt, C. Dore, and P. B. Medawar. 1985. Influence of dendritic cells on tumor growth. Proc. Natl. Acad. Sci. USA 82: 4495–4497.PubMedCrossRefGoogle Scholar
  25. 25.
    Krikorian, J., C. Portlock, D. Cooney, and S. Rosenberg. 1980. Spontaneous regression of non-Hodgkin’s lymphoma. A report of nine cases. Cancer 46: 2093–2099.PubMedCrossRefGoogle Scholar
  26. 26.
    Lindhout, E., C. G. Figdor, and G. J. Adema. 1998. Dendritic cells: migratory cells that are attractive. Cell Adhes. Commun. 6: 117–123.PubMedCrossRefGoogle Scholar
  27. 27.
    Maraskovsky, E., McKenna, H., and Brasel, K. 1995. In vivo administration of Flt3 ligand but not G-CSF nor GM-CSF results in the generation of large numbers of dendritic cells in mice. Blood 86: 423a (Abstract 1680 ).Google Scholar
  28. 28.
    Marrack, P. and J. Kappler. 1987. The T cell receptor. Science 238: 1073–1079.PubMedCrossRefGoogle Scholar
  29. 29.
    Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1: 1297–1302.PubMedCrossRefGoogle Scholar
  30. 30.
    Melder, R. J., T. L. Whiteside, N. L. Vujanovic, J. C. Hiserodt, and R. B. Herberman. 1988. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. 48: 3461–3469.PubMedGoogle Scholar
  31. 31.
    Mellman, I., S. J. Turley, and R. M. Steinman. 1998. Antigen processing for amateurs and professionals. Trends Cell Biol. 8: 231–237.PubMedCrossRefGoogle Scholar
  32. 32.
    Middleton, R., J. Smith, R. Melzer, and P. Hamilton. 1986. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J. Urol. 136: 422–424.PubMedGoogle Scholar
  33. 33.
    Mitropoulos, D., S. Kooi, J. Rodriguez-Villanueva, and C. D. Platsoucas. 1994. Characterization of fresh (uncultured) tumour-inflitrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97: 321–327.PubMedCrossRefGoogle Scholar
  34. 34.
    Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Ragde, et al. 1999. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory prostate cancer. Prostate 38: 73–78.PubMedCrossRefGoogle Scholar
  35. 35.
    Murphy, G. P., B. A. Tjoa, S. J. Simmons, H. Ragde, M. Rogers, A. Elgamal, et al. 1999. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment [In Process Citation]. Prostate 39: 54–59.PubMedCrossRefGoogle Scholar
  36. 36.
    Murphy, G., H. Ragde, G. Kenny, R. Barren III, S. Erickson, B. Tjoa, et al. 1995. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15: 1473–1480.PubMedGoogle Scholar
  37. 37.
    Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201specific peptides from prostate-specific membrane antigen. Prostate 29: 371–380.PubMedCrossRefGoogle Scholar
  38. 38.
    Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, et al. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328–332.PubMedCrossRefGoogle Scholar
  39. 39.
    Oh, W. K. and P. W. Kantoff. 1998. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 160: 1220–1229.PubMedCrossRefGoogle Scholar
  40. 40.
    Ragde, H. 1997. Brachytherapy (seed implantation) for clinically localized prostate cancer. J. Surg. Oncol. 64: 79–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Ragde, H., A. Elgamal, P. Snow, J. Brandt, A. Bartolucci, B. Nadir, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83: 989–1001.Google Scholar
  42. 42.
    Ralfkiaer, E., K. Hou-Jensen, K. Gatter, D. Drzewiecki, and D. Mason. 1987. Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. 410: 355–361.CrossRefGoogle Scholar
  43. 43.
    Ravindranath, M. H., D. L. Morton, and R. F. Irie. 1989. An epitope common to ganglio-sides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 49: 3891–3897.PubMedGoogle Scholar
  44. 44.
    Romani, N., D. Reider, M. Heuer, S. Ebner, and E. Kempgen. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137–151.PubMedCrossRefGoogle Scholar
  45. 45.
    Rosenberg, S. A. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88: 1635–1644.PubMedCrossRefGoogle Scholar
  46. 46.
    Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319: 1676–1680.PubMedCrossRefGoogle Scholar
  47. 47.
    Ruiter, D. J., A. K. Bhan, T. J. Harrist, A. J. Sober, and M. Mhim-Jr. 1982. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J. Immunol. 129: 2808–2815.PubMedGoogle Scholar
  48. 48.
    Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56: 4749–4757.PubMedGoogle Scholar
  49. 49.
    Sallusto, F. and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109–1118.PubMedCrossRefGoogle Scholar
  50. 50.
    Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J. Exp. Med. 182: 389–400.PubMedCrossRefGoogle Scholar
  51. 51.
    Scher, H. I., G. Steineck, and W. K. Kelly. 1995. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142–148.PubMedCrossRefGoogle Scholar
  52. 52.
    Sedlacek, H. 1994. Vaccination for treatment of tumors: a critical comment. Critical Rev. Oncog. 5: 555–587.Google Scholar
  53. 53.
    Siegall, C. B. 1994. Targeted toxins as anticancer agents. Cancer 74: 1006–1012.PubMedCrossRefGoogle Scholar
  54. 54.
    Simmons, S. J., B. A. Tjoa, M. Rogers, A. Elgamal, G. M. Kenny, H. Ragde, et al. 1999. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39: 291–297.PubMedCrossRefGoogle Scholar
  55. 55.
    Slovin, S. F., W. K. Kelly, and H. I. Scher. 1998. Immunological approaches for the treatment of prostate cancer. Sem. Urol. Oncol. 16: 53–59.Google Scholar
  56. 56.
    Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271–296.PubMedCrossRefGoogle Scholar
  57. 57.
    Thomas, R., L. S. Davis, and P. E. Lipsky. 1993. Isolation and characterization of human peripheral blood dendritic cells. J. Immunol. 150: 821–829.PubMedGoogle Scholar
  58. 58.
    Tjoa, B. A., S. J. Simmons, A. Elgamal, M. Rogers, H. Ragde, G. M. Kenny, et al. 1999. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125–129.PubMedCrossRefGoogle Scholar
  59. 59.
    Tjoa, B., S. Erickson, R. Barren III, H. Ragde, G. Kenny, A. Boynton, et al. 1995. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 27: 63–69.PubMedCrossRefGoogle Scholar
  60. 60.
    Tjoa, B., S. Erickson, V. Bowes, H. Ragde, G. Kenny, O. Cobb, et al. 1997. Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272–278.PubMedCrossRefGoogle Scholar
  61. 61.
    Tjoa, B., S. Simmons, V. Bowes, H. Ragde, M. Rogers, A. Elgamal, et al. 1998. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 39–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Topalian, S., D. Solomon, F. P. Avis, A. E. Chang, D. L. Freerksen, W. M. Linehan, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 6: 839–853.PubMedGoogle Scholar
  63. 63.
    Urban, J. L. and H. Schreiber. 1992. Tumor antigens. Ann. Rev. Immunol. 10: 617–644.CrossRefGoogle Scholar
  64. 64.
    Walsh, P. C., A. W. Partin, and J. I. Epstein. 1994. Cancer control and quality of life following anatomic radical retropubic prostatectomy. Results at 10 years. J. Urol. 152: 1831–1836.PubMedGoogle Scholar
  65. 65.
    Wang, M., L. Valenzuela, G. Murphy, and T. Chu. 1979. Purification of a human prostate-specific antigen. Investig. Urol. 17: 159–163.Google Scholar
  66. 66.
    Young, J. W. and R. M. Steinman. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte response in the absence of CD4+ helper T cells. J. Exp. Med. 171: 1315–1332.PubMedCrossRefGoogle Scholar
  67. 67.
    Zinkernagel, R. M. and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248: 701, 702.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Benjamin A. Tjoa
  • Gerald P. Murphy

There are no affiliations available

Personalised recommendations